Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
|Articles|May 8, 2006
Pneumococcal vaccine now in prefilled syringes
Wyeth Pharmaceutical's Prevnar (pneumococcal 7-valent conjugatevaccine) is now being manufactured in single-dose, prefilledsyringes.
Advertisement
Wyeth Pharmaceutical's Prevnar (pneumococcal 7-valent conjugate vaccine) is now being manufactured in single-dose, prefilled syringes. This new packaging will allow the vaccine to be administered directly from the syringe, thereby reducing the risk for dosing errors. The company will no longer be manufacturing the previously available vials of Prevnar vaccine. The new syringes will be sold in packages of 10.
To see more Hot off the Press news articles, click here
To go to the Drug Topics homepage,
Advertisement
Related to this article
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
5